GLP-1 Self-Pay Options: How LillyDirect and NovoCare Compare

Write down the brand name, the form (weekly injection pen, vial, or daily pill), and the strength your prescriber discussed. These details matter because pricing and availability can differ by form even within the same brand. Also note whether you are switching from a compounded version to an FDA-approved product, since pharmacies may ask for different information. Keep your prescriber’s office contact details handy in case a pharmacy needs to verify your prescription.

LillyDirect is a manufacturer channel that can route you to telehealth (if appropriate) and participating pharmacies for Lilly medicines. NovoCare is the manufacturer support channel for Novo Nordisk medicines and may point you to savings tools and fulfillment options. At the time of writing, a federal site called TrumpRx.gov also lists the lowest manufacturer self-pay prices and routes you to the maker’s channel, but it is not insurance. Prices and programs change often, so confirm current pricing and eligibility directly with the manufacturer, your plan, or your pharmacist.

As of this date, there are newer FDA-approved choices that change the daily logistics for some people. Wegovy pill (oral semaglutide 25 mg) launched in January 2026 and must be taken first thing in the morning with a small sip of water, at least 30 minutes before food, drinks, or other oral medicines. Foundayo (orforglipron) launched in April 2026 and is a once-daily GLP-1 pill with no fasting or water restrictions and can be taken any time of day. Bring your routine and preferences to your prescriber so they can help you decide what is medically appropriate.

If you use Zepbound, note that the Zepbound KwikPen (a multi-dose pen) was approved in February 2026; one device holds a month of doses, and it comes in all six strengths (2.5–15 mg). Single-dose pens and vials also exist, so your pharmacy experience and pricing may vary by format. If you use Wegovy, Wegovy HD (semaglutide 7.2 mg injection) was FDA approved in March 2026 for chronic weight management, and it may be discussed for some patients. Do not change your medication form or strength based on price alone—confirm the exact prescription details with your prescriber.

A self-pay price is not the same as insurance coverage, and a savings card is not guaranteed for everyone. At the time of writing, Foundayo started with a self-pay option beginning at $149/month for the lowest dose, and a commercial savings card could be as low as $25/month for eligible patients. If you have Medicare, a temporary CMS demonstration called the Medicare GLP-1 Bridge (July 1, 2026 to December 31, 2027) offers a $50/month copay for eligible Part D enrollees for Wegovy (all forms), Foundayo, and Zepbound KwikPen, with prior authorization rules. Confirm eligibility directly with your Part D plan and your prescriber’s office, because coverage paths can differ if you have type 2 diabetes or moderate-to-severe sleep apnea.

Be cautious with online listings that promise cheaper versions of brand-name GLP-1s or “next-generation” drugs. Retatrutide is still in late-stage trials and is not approved; anything sold online under that name is unapproved and not legally prescribable outside trials. CagriSema has been submitted to the FDA but is not approved as of this date. If you are offered a product that is not FDA-approved or is labeled “for research use,” pause and ask your prescriber or pharmacist to help you verify what it is before you pay.